BMPR2 and pulmonary arterial hypertension: These data identified ataluren as a capable drug to treat PAH as it can effectively suppresses BMPR2 and SMAD9 nonsense mutations and correct several aspects of BMP signalling through regulation of miR-27 in ECs (Drake et al., 2013[26]).